Recent Drug Approvals for Rare Kidney Diseases
Published:
Rare kidney disease drugs are becoming an increasingly important component of nephrology care, particularly as treatment strategies shift toward slowing disease progression by addressing the underlying mechanisms of renal injury. In this context, emerging therapies are targeting proteinuria and disease-driving pathways through approaches such as anti-APRIL agents, complement inhibitors, and endothelin A receptor antagonism. These approaches have demonstrated their potential in the preservation of kidney function and thereby delayed progression towards kidney failure.
The clinical relevance of such therapies is increasing amid the inherent challenges of progressive rare kidney diseases, including limited patient pools and difficulties in biomarker discovery. These targeted interventions have the potential to address specific pathological processes, including abnormal immune activation, complement-mediated kidney injury, and endothelin-driven inflammation and vasoconstriction. Further, the expanding therapeutic landscape is broadening treatment possibilities across indications such as IgA nephropathy, other protein uric kidney disorders and chronic kidney diseases.
As the rare kidney diseases drugs market advances across specialized nephrology and chronic care settings, pharmaceutical companies are investing in targeted small molecules and biologics designed to modify disease progression rather than solely manage its consequences. This evolving pipeline is creating opportunities to expand treatment options, develop mechanism-specific therapies, and address substantial unmet needs among patients with rare and progressive kidney diseases.
Roots Analysis has conducted an exhaustive study on the Rare Kidney Diseases Drugs Market, featuring the current market landscape and future opportunities for companies engaged in this therapeutic area over the next 14 years.
Recently Approved Rare Kidney Diseases Drugs
1. Trutakna
2. Filspari®
3. Fabhalta®
4. Aspaveli®
5. Elfabrio®
The figure below highlights the five recently approved drugs for rare kidney diseases:

Interested in exploring all ~170 rare kidney disease therapy programs, along with their recent initiatives?
Discover Below the Details on Recently Approved Rare Kidney Diseases Drugs
Let us dive deep into the details of the key 5 approved rare kidney diseases drugs approved in the last couple of years.
1. Trutakna
The section provides information on various parameters, with details on developer, type of molecule, type of biologic, type of therapy, route of administration, mechanism of action, and target indication.
- Developer: Vera Therapeutics
- Generic Name: Atacicept
- Type of Molecule: Biologic
- Type of Biologic: Protein / Peptide
- Route of Administration: Subcutaneous
- Mechanism of Action: BAFF inhibition, APRIL inhibition
- Type of Therapy: Monotherapy
- Target Patient Population: Children, Adults, Elderly Patients
- Target Indications: Immunoglobulin A Nephropathy (Approved), Membranous Nephropathy, Focal Segmental Glomerulosclerosis
Recent Developments
In July 2026, the FDA granted accelerated approval to Trutakna (Atacicept), to reduce the levels of proteinuria in adult patients with Immunoglobulin A Nephropathy and at risk of disease progression.
To know more about Trutakna® and other recently approved rare kidney diseases drugs, access full report.
2. Filspari®
The section provides information on various parameters, with details on developer, type of molecule, type of therapy, route of administration, mechanism of action, and target indication.
- Developer: Travere Therapeutics
- Generic Name: Sparsentan
- Type of Molecule: Small Molecule
- Route of Administration: Oral
- Mechanism of Action: Endothelin and angiotensin II receptor antagonism
- Type of Therapy: Monotherapy
- Target Patient Population: Children, Adults, Elderly Patients
- Target Indications: Focal Segmental Glomerulosclerosis (Approved), Immunoglobulin A Nephropathy (Approved), Alport Syndrome
Recent Developments
In April 2026, the FDA granted approval to Filspari (Sparsentan), for the treatment of Focal Segmental Glomerulosclerosis. It is worth mentioning that Filspari is first ever FDA approved drug for this indication.
To know more about Filspari and other recently approved rare kidney diseases drug, access full report.
3. Fabhalta®
The section provides information on various parameters, with details on developer, type of molecule, type of therapy, route of administration, mechanism of action, and target indication.
- Developer: Novartis
- Generic Name: Iptacopan
- Type of Molecule: Small Molecule
- Route of Administration: Oral
- Mechanism of Action: Complement factor B inhibition
- Type of Therapy: Monotherapy
- Target Patient Population: Children, Adults, Elderly Patients
- Target Indications: Immunoglobulin A Nephropathy (Approved), Complement 3 Glomerulopathy (Approved), Immune Complex Membranoproliferative Glomerulonephritis
Recent Developments
In July 2026, the FDA granted approval to Fabhalta® (Iptacopan), to slow down kidney function decline in adults with immunoglobulin A nephropathy.3 The drug received FDA approval earlier for reducing proteinuria in patients with immunoglobulin A nephropathy and complement 3 glomerulopathy, and it is currently being studied for immune complex membranoproliferative glomerulonephritis.
To know more about Fabhalta® and other recently approved rare kidney diseases drug, access full report.
4. Aspaveli®
The section provides information on various parameters, with details on developers, type of molecule, type of biologic, type of therapy, route of administration, mechanism of action, and target indication.
- Developers: Apellis Pharmaceuticals, Sobi
- Generic Name: Pegcetacoplan
- Type of Molecule: Biologic
- Type of Biologic: Protein / Peptide
- Route of Administration: Subcutaneous
- Mechanism of Action: Complement inhibitor
- Type of Therapy: Combination (with Renin-angiotensin system (RAS) inhibitor)
- Target Patient Population: Adolescents, Adults
- Target Indications: Complement 3 Glomerulopathy (Approved), Immune Complex Membranoproliferative Glomerulonephritis
Recent Developments
In January 2026, the EMA granted approval to Aspaveli® (Pegcetacoplan), for the treatment of complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. The drug had received FDA approval in the previous year, marking its earlier regulatory authorization in the United States.
To know more about Aspaveli® and other recently approved rare kidney diseases drug, access full report.
5. Elfabrio®
The section provides information on various parameters, with details on developer, type of molecule, type of biologic, type of therapy, route of administration, mechanism of action, and target indication.
- Developer: Protalix Biotherapeutics
- Generic Name: Pegunigalsidase Alfa
- Type of Molecule: Biologic
- Type of Biologic: Enzymes
- Route of Administration: Intravenous
- Mechanism of Action: Reduce accumulated globotriaosylceramide (Gb3)
- Type of Therapy: Monotherapy
- Target Patient Population: Adults
- Target Indications: Fabry Disease
Recent Developments
In March 2026, the European Commission granted approval to Elfabrio® (Pegunigalsidase Alfa), for the treatment of patients with fabry disease with new dose regimen of 2mg/kg every four weeks. The drug had previously been approved for administration at the same dose, but a different dosage regimen (every two weeks).
To know more about Elfabrio® and other recently approved rare kidney diseases drug, access full report.
What About Other Rare Kidney Diseases Drugs / Therapy Programs Around the World?
The above article features the recently approved rare kidney diseases drugs selected from a pool of over 170 rare kidney diseases therapy programs that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
1. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy
2. https://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition
3. https://www.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-first-and-only-complement-inhibitor-significantly-slow-kidney-function-decline-primary-igan
4. https://www.sobi.com/en/press-releases/sobi-receives-european-commission-approval-aspavelir-pegcetacoplan-treatment-c3g-and-primary-ic-mpgn-2418695
5. https://www.chiesi.com/en/media-hub/press-releases/elfabrio-european-commission-approval-four-week-dosing